Company news
Biovie Inc. (NASDAQ:BIVI) news
Every Biovie Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
BioVie Announces Update to Parkinson's Phase 3 Development Program
September 9, 2026
BioVie Announces Update to Parkinson’s Phase 3 Development Program
September 8, 2026
BioVie Announces Completion of Treatment Phase of ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated wi...
August 31, 2026
BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson’s Disease
August 6, 2026
Join BioVie’s Exclusive Live Investor Webinar and Q and A Session on June 2
May 27, 2026
BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
May 26, 2026
BioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson’s Disease
May 18, 2026
Bioventus Reports First Quarter Financial Results
May 6, 2026
BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Dat...
April 27, 2026
BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting
April 14, 2026
BioVie Announces Abstract Accepted for Presentation at AD/PD 2026
March 12, 2026
Join Biovie’s Exclusive Live Investor Webinar and Q&A Session on March 4
February 23, 2026
BioVie Announces Abstracts Accepted for Presentation at the 2026 American College of Psychiatrists Annual Meeting
February 12, 2026
BioVie Completes Enrollment in Phase 2 SUNRISE-PD Trial in Early Parkinson’s Disease
January 8, 2026
Bench International Announces Appointment of Jim Lang to the Board of Directors of Halozyme Therapeutics
December 17, 2025
Join Biovie’s Exclusive Live Investor Webinar and Q&A Session on December 9
November 19, 2025
BioVie to Host Live Investor Webinar and Q&A on Oct. 8
September 26, 2025
BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keyst...
August 13, 2025
BioVie Inc. Announces Closing of $12 Million Public Offering
August 11, 2025
BioVie Inc. Announces Pricing of $12 Million Public Offering
August 7, 2025
BioVie Presented Data Highlighting that Patients Treated with Bezisterim Potentially Experienced an Age Deceleration Advantage Compared t...
July 24, 2025
BioVie Appoints Industry Veterans Amy Chappell, MD, FAAN, and Kameel Farag to Board of Directors
July 22, 2025
BioVie Announces Data Highlighting Bezisterim’s Potential to Slow or Reverse Biological Aging and Neurodegeneration Featured as a Keynote...
July 9, 2025
BioVie Highlights Patient-Centric Design of SUNRISE-PD Trial at Advanced Therapeutics in Movement & Related Disorders® Congress (ATMRD)
June 26, 2025
BioVie to Present Overview of Phase 2 SUNRISE-PD Trial at the Advanced Therapeutics in Movement & Related Disorders® Congress
June 24, 2025
BioVie Enrolls First Patient in ADDRESS-LC Clinical Trial Assessing Novel Anti-Inflammatory Candidate Bezisterim for the Treatment of Neu...
May 15, 2025
BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease on May 28, 2025
May 14, 2025
BioVie to Present Rationale and Design of Phase 2 SUNRISE-PD Clinical Trial at the 30th World Congress on Parkinson’s Disease and Related...
May 7, 2025
BioVie Unveils Corporate Advisory Board Featuring Neuralink Co-Founder, Former Executives from Mastercard and Apple, and High-Impact Indu...
May 5, 2025
BioVie Initiates SUNRISE-PD Clinical Trial Assessing Bezisterim in Early Parkinson’s Disease with First Patient Enrolled
April 16, 2025
BioVie to Host KOL Investor Webcast to Discuss the Long COVID Treatment Landscape and its ADDRESS-LC Trial on April 10, 2025
March 27, 2025
BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID Internatio...
November 20, 2024
BioVie’s Upcoming Parkinson’s Disease Clinical Trial is Fully Funded
November 4, 2024
BioVie Inc. Announces Closing of Registered Direct Offering
October 29, 2024
BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
October 28, 2024
BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement
October 24, 2024
Join BioVie’s Exclusive Live Investor Webinar and Q&A Session on November 7th, 2024
October 23, 2024
BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
October 23, 2024
BioVie Receives Notice of Allowance for Japan Patent Application Covering Novel Liquid Formulation of Terlipressin
October 15, 2024
BioVie Receives Notice of Allowance for United States Patent Application Covering Novel Liquid Formulation of Terlipressin
October 1, 2024
BioVie Inc. Announces Closing of Public Offering
September 25, 2024
BioVie Inc. Announces Proposed Public Offering
September 23, 2024
BioVie Inc. Announces Pricing of Public Offering
September 23, 2024
BioVie Secures All Scientific Approvals Needed to Receive Additional $12.6 Million of Grant Funding to Launch Planned Phase 2 Trial to Ev...
September 16, 2024
BioVie Announces FDA Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long COVID
September 3, 2024
BioVie Announces Clinical Data Showing Epigenetic Basis for How Bezisterim May Modulate Inflammation and the Biological Aging Process at ...
August 27, 2024
BioVie to Present Overview of Bezisterim Clinical Data on Longevity at 11th Aging Research and Drug Discovery Meeting
August 13, 2024
BioVie Announces Alignment with FDA on Clinical Trial to Assess Bezisterim in Parkinson’s Disease
August 8, 2024
BioVie Inc. Announces Reverse Stock Split
August 6, 2024
BioVie Presents Protocol Design of Upcoming SUNRISE-PD Phase 2 Trial of Bezisterim in Patients with Early Parkinson’s Disease at ATMRD 2024
June 25, 2024